{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:08:53Z","timestamp":1789470533778,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30DA040500"],"award-info":[{"award-number":["P30DA040500"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA035808"],"award-info":[{"award-number":["R01DA035808"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA046721"],"award-info":[{"award-number":["R01DA046721"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jval.2020.12.023","type":"journal-article","created":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T18:01:24Z","timestamp":1620496884000},"page":"1068-1083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review"],"prefix":"10.1016","volume":"24","author":[{"given":"Erica N.","family":"Onuoha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared A.","family":"Leff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Schackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"McCollister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Polsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2020.12.023_bib4","first-page":"1419","article-title":"Drug and opioid-involved overdose deaths\u2014United States, 2013-2017","volume":"67","author":"Scholl","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jval.2020.12.023_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108382","article-title":"The cost of opioid use disorder and the value of aversion","volume":"217","author":"Murphy","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jval.2020.12.023_bib8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"3","key":"10.1016\/j.jval.2020.12.023_bib9","doi-asserted-by":"crossref","first-page":"190","DOI":"10.7326\/M18-1397","article-title":"Overdose prevention through medical treatment of opioid use disorders","volume":"169","author":"Volkow","year":"2018","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.jval.2020.12.023_bib10","first-page":"358","article-title":"American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use","volume":"9","author":"Kampman","year":"2015","journal-title":"J\u00a0Addict Med"},{"issue":"10182","key":"10.1016\/j.jval.2020.12.023_bib11","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(18)33078-2","article-title":"Management of opioid use disorder in the USA: present status and future directions","volume":"393","author":"Blanco","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jval.2020.12.023_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/0976-3147.91934","article-title":"Buprenorphine vs methadone treatment: a review of evidence in both developed and developing worlds","volume":"3","author":"Whelan","year":"2012","journal-title":"J\u00a0Neurosci Rural Pract"},{"issue":"8","key":"10.1016\/j.jval.2020.12.023_bib13","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/17512433.2019.1635454","article-title":"Buprenorphine treatment for opioid use disorder: recent progress","volume":"12","author":"Parida","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jval.2020.12.023_bib15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/00952990.2011.653426","article-title":"Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice","volume":"38","author":"Sigmon","year":"2012","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1","key":"10.1016\/j.jval.2020.12.023_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13011-019-0199-0","article-title":"Strengthening partnerships between substance use researchers and policy makers to take advantage of a window of opportunity","volume":"14","author":"Meisel","year":"2019","journal-title":"Subst Abus Treat Prev Policy"},{"issue":"9","key":"10.1016\/j.jval.2020.12.023_bib17","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40273-016-0400-5","article-title":"Economic evaluations of opioid use disorder interventions","volume":"34","author":"Murphy","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2020.12.023_bib18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13643-017-0644-y","article-title":"Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study","volume":"6","author":"Bramer","year":"2017","journal-title":"Syst Rev"},{"issue":"8","key":"10.1016\/j.jval.2020.12.023_bib19","first-page":"893","article-title":"Cost-effectiveness of subdermal implantable buprenorphine versus sublingual buprenorphine to treat opioid use disorder","volume":"20","author":"Carter","year":"2017","journal-title":"J\u00a0Med Econ"},{"issue":"7","key":"10.1016\/j.jval.2020.12.023_bib20","first-page":"740","article-title":"Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study","volume":"20","author":"Kenworthy","year":"2017","journal-title":"J\u00a0Med Econ"},{"issue":"4","key":"10.1016\/j.jval.2020.12.023_bib21","first-page":"406","article-title":"Healthcare utilization and costs associated with treatment for opioid dependence","volume":"21","author":"Shah","year":"2018","journal-title":"J\u00a0Med Econ"},{"issue":"5","key":"10.1016\/j.jval.2020.12.023_bib22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S2215-0366(19)30097-5","article-title":"Efficacy and cost-effectiveness of an adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trial","volume":"6","author":"Marsden","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"10.1016\/j.jval.2020.12.023_bib23","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/add.13807","article-title":"Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder","volume":"112","author":"Murphy","year":"2017","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.jval.2020.12.023_bib24","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/add.13729","article-title":"The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California","volume":"112","author":"Krebs","year":"2017","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.jval.2020.12.023_bib25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1089\/pop.2018.0163","article-title":"Integration of buprenorphine treatment with primary care: comparative effectiveness on retention, utilization, and cost","volume":"22","author":"Hsu","year":"2018","journal-title":"Popul Health Manag"},{"key":"10.1016\/j.jval.2020.12.023_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsat.2016.05.002","article-title":"Impact of medication-assisted treatment for opioid addiction on Medicaid expenditures and health services utilization rates in Vermont","volume":"67","author":"Mohlman","year":"2016","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"1","key":"10.1016\/j.jval.2020.12.023_bib27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13011-016-0087-9","article-title":"Implementation of methadone therapy for opioid use disorder in Russia\u2013a modeled cost-effectiveness analysis","volume":"12","author":"Idrisov","year":"2017","journal-title":"Subst Abus Treat Prev Policy"},{"key":"10.1016\/j.jval.2020.12.023_bib28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.drugalcdep.2016.09.008","article-title":"Cost-effectiveness of center-based compulsory rehabilitation compared to community-based voluntary methadone maintenance treatment in Hai Phong City, Vietnam","volume":"168","author":"Vuong","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"10.1016\/j.jval.2020.12.023_bib29","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/j.1360-0443.2012.03888.x","article-title":"Compulsory detention, forced detoxification and enforced labour are not ethically acceptable or effective ways to treat addiction","volume":"107","author":"Hall","year":"2012","journal-title":"Addiction"},{"issue":"12","key":"10.1016\/j.jval.2020.12.023_bib30","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/add.13073","article-title":"A\u00a0cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among\u00a0people with a history of opioid dependence","volume":"110","author":"Gisev","year":"2015","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.jval.2020.12.023_bib31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M17-0611","article-title":"Cost-effectiveness of publicly funded treatment of opioid use disorder in California","volume":"168","author":"Krebs","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2020.12.023_bib32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jsat.2018.07.014","article-title":"Re-engineering methadone-cost-effectiveness analysis of a patient-centered approach to methadone treatment","volume":"94","author":"Dunlap","year":"2018","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"9","key":"10.1016\/j.jval.2020.12.023_bib33","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1056\/NEJMp1109283","article-title":"Shared decision making\u2014the pinnacle of patient-centered care","volume":"366","author":"Barry","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.jval.2020.12.023_bib34","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1111\/add.13900","article-title":"Cost-effectiveness of emergency department-initiated treatment for opioid dependence","volume":"112","author":"Busch","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.jval.2020.12.023_bib35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.drugalcdep.2017.01.016","article-title":"Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial","volume":"174","author":"Dunlop","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jval.2020.12.023_bib36","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.drugpo.2019.05.010","article-title":"Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV\/hepatitis C co-infection who inject opioids","volume":"72","author":"Barocas","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"3","key":"10.1016\/j.jval.2020.12.023_bib37","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/add.14797","article-title":"Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis","volume":"115","author":"Morozova","year":"2020","journal-title":"Addiction"},{"issue":"7","key":"10.1016\/j.jval.2020.12.023_bib38","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/add.14171","article-title":"Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial","volume":"113","author":"Bansback","year":"2018","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.jval.2020.12.023_bib39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/15360288.2015.1135847","article-title":"Office-based buprenorphine versus clinic-based methadone: a cost-effectiveness analysis","volume":"30","author":"King","year":"2016","journal-title":"J\u00a0Pain Palliat Care Pharmacother"},{"issue":"4","key":"10.1016\/j.jval.2020.12.023_bib40","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40258-014-0102-0","article-title":"Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using\u00a0administrative claims data","volume":"12","author":"Rice","year":"2014","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"10.1016\/j.jval.2020.12.023_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3810\/pgm.2014.07.2783","article-title":"The economic burden of diagnosed opioid abuse among commercially insured individuals","volume":"126","author":"Rice","year":"2014","journal-title":"Postgrad Med"},{"issue":"6","key":"10.1016\/j.jval.2020.12.023_bib42","first-page":"469","article-title":"Direct costs of opioid abuse in an insured population in the United States","volume":"11","author":"White","year":"2005","journal-title":"J\u00a0Manag Care Pharm"},{"issue":"5","key":"10.1016\/j.jval.2020.12.023_bib43","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/AOG.0000000000003503","article-title":"Methadone, buprenorphine, or detoxification for management of perinatal opioid use disorder: a cost-effectiveness analysis","volume":"134","author":"Premkumar","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.jval.2020.12.023_bib45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.7326\/M18-0227","article-title":"Cost-effectiveness of buprenorphine\u2013naloxone versus extended-release naltrexone to prevent opioid relapse","volume":"170","author":"Murphy","year":"2019","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jval.2020.12.023_bib46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1478-7547-11-6","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) statement","volume":"11","author":"Husereau","year":"2013","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.jval.2020.12.023_bib47","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"issue":"5","key":"10.1016\/j.jval.2020.12.023_bib48","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/00019053-200826050-00003","article-title":"Economic evaluation of interventions to treat opiate dependence","volume":"26","author":"Doran","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2020.12.023_bib49","doi-asserted-by":"crossref","first-page":"B5","DOI":"10.1016\/j.ajog.2019.03.022","volume":"221","author":"Ecker","year":"2019","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.jval.2020.12.023_bib50","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jval.2020.12.023_bib51","series-title":"Cost-Effectiveness in Health and Medicine","author":"Neumann","year":"2016"},{"key":"10.1016\/j.jval.2020.12.023_bib52","series-title":"Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis","author":"Tan-Torres Edejer","year":"2003"},{"issue":"1","key":"10.1016\/j.jval.2020.12.023_bib53","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1472-6963-6-52","article-title":"Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation","volume":"6","author":"Fenwick","year":"2006","journal-title":"BMC Health Serv Res"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521001546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521001546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:23:03Z","timestamp":1761096183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301521001546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1098301521001546"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.12.023","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}